The prognosis for most patients with esophageal adenocarcinoma (EAC) is poor because they present with advanced disease. Models developed to identify patients at risk for EAC and increase early detection have been developed based on data from case-control studies. We analyzed data from a prospective study to identify factors available to clinicians that identify individuals with a high absolute risk of EAC.
T he incidence of esophageal adenocarcinoma (EAC) is increasing in Western populations, 1 and prognosis is poor. Overall survival is <20%. 2 Methods to improve early diagnosis are important 3 because the poor survival is largely attributable to late clinical presentation with advanced disease. 2 Endoscopy with biopsies for histologic confirmation is the gold standard method of detecting esophageal and gastric cancers. 4, 5 However, population-wide endoscopy screening programs are unlikely to be cost-effective or feasible because of the low incidence of upper gastrointestinal cancers and the cost, invasiveness, and psychological burden of endoscopy screening.
Clinical guidelines suggest that individuals with chronic symptomatic gastroesophageal reflux disease (GERD) should be referred for endoscopy screening to identify Barrett's esophagus, 7 a precursor to EAC present in 1%-2% of the adult population. 8 Individuals with Barrett's esophagus are often entered into endoscopy surveillance programs. 9 Use of GERD as the sole initial triage factor for endoscopy is appealing in its simplicity, but delays in obtaining endoscopy are common in part because of a lack of both specificity, because risk of EAC in individuals with GERD is low, 10, 11 and sensitivity, because a large proportion of EAC cases (w40%) never report GERD symptoms. 11 Automated clinical risk prediction tools using data easily accessible to primary care physicians to flag highrisk individuals may offer a lower cost method to improve early detection and are being investigated for other conditions. 12 Established risk factors including body mass index (BMI), smoking status, and GERD may be useful for risk prediction of EAC [13] [14] [15] and Barrett's esophagus. [16] [17] [18] However, existing studies have relied on age and sex matched case-control data, which may be subject to recall bias and ignore age and sex in improving the risk prediction, which are strong risk factors. 19 An assessment of traditional risk factors may be useful as triage directly to endoscopy, in which case risk prediction for any upper gastrointestinal cancers diagnosed via endoscopy would be most informative. However, it seems likely that EAC risk prediction will require a multistage screening strategy, 20 of which some steps may be specific to EAC.
We aimed to use prospective data from the UK Biobank to develop a risk-prediction model that is based on a combination of factors widely available to clinicians that may predict risk of EAC development within 5 years. Secondary analyses aimed to develop and assess a riskprediction model that predicts risk of all upper gastrointestinal cancers detected via endoscopy.
Methods

Study Design
This cohort study used prospective data from the UK Biobank, which recruited 502,640 men and women aged 40-69 years from 1 of 22 centers located across England, Scotland, and Wales between 2006 and 2010. 21 Approximately 9.2 million individuals registered with the National Health Service living within a 25-mile radius of 1 of the 22 centers were invited to participate. The response rate was 5.5% (n ¼ 503,325). 22 Included in the present study were individuals aged 50 years (because upper gastrointestinal cancers are rare in those aged <50), without a history of cancer (excluding nonmelanoma skin cancer) at or before baseline or within 6 months after baseline (to exclude diagnostic delays) and with complete information on relevant risk factors.
The UK Biobank was approved by the North West Multi-Centre Research Ethics Committee, and all participants provided written informed consent.
Assessment and Classification of Candidate Predictor Variables
Participants were asked to complete electronic touchscreen questionnaires at baseline, which inquired about a wide range of potential risk factors for chronic diseases, and have anthropometric measurements taken (Supplementary Methods). Self-reported current medication use, medical history, and surgical history were assessed via the electronic touchscreen questionnaire and were verified during a face-to-face interview with a trained nurse with responses matched to a coding tree, where possible, by a doctor.
Candidate predictor variables widely available to clinicians, such as age and BMI, were identified and categorized a priori from the literature (Table 1) . [23] [24] [25] [26] [27] Additional candidate predictor variables not thought to be widely available to clinicians, such as waist: hip ratio and others that do not have as strong evidence for an association with EAC, were treated separately and only included if they added independent predictive value (Supplementary Table 1 ).
Outcome Assessment
The UK Biobank is regularly linked to UK cancer registry data from the Health and Social Care Information Centre (in England and Wales), the Scottish Cancer Registry (in Scotland), and death records from the UK Office of National Statistics. Cancer data were provided up until September 30, 2014. Newly diagnosed cancers were classified by site according to International Classification of Diseases, 10 th version (ICD/10) and histology (ICD-O morphology codes). Primary EACs (ICD/10 C15, with ICD-O 8140-8573) diagnosed between 6 months (because of potential diagnostic delays) and 5 years from baseline were the main outcome of interest. Secondary outcomes included all primary upper gastrointestinal cancers (ICD/10 C15 and C16), esophageal cancer (ICD-10 C15, regardless of histology), gastric cancer (ICD-10 C16, regardless of histology), and esophageal squamous cell carcinoma (ICD-10 C15, ICD-O 8050-8082) diagnosed between 6 months and 5 years from baseline. Information on tumor stage was not available.
Statistical Analysis
Stepwise logistic regression was used to estimate factors widely available to clinicians associated with risk of EAC within 5 years (P < .1).
Points-based models were created from the coefficient-based model by dividing the coefficient of each variable by the smallest coefficient in the model and rounding to the nearest 0.5 to allow ease of calculation without a computer and easier to interpret cutoffs. 28 For example, the coefficient for men was 1.64, and the smallest coefficient in the model was 0.40 (BMI, 25 to <30 kg/m 2 ), so men were assigned 4 points (1.64/0.40, then rounded to nearest 0.5).
Diagnostic accuracy was quantified for the simple factor coefficient-and points-based model, additional factor coefficient-and points-based model by using the area under the receiver operating characteristic (AUROC) curve with 95% confidence interval (CI). An internally validated AUROC was calculated by using bootstrap methods described by Steyerberg et al, 29 accounting for optimism in model selection (including the stepwise selection procedure) and performance. Goodness-of-fit was assessed by using Hosmer-Lemeshow tests and calibration curves.
AUROC, sensitivity, specificity, Youden's index (sensitivity þ specificity -1), risk of EAC within 5 years (equivalent to positive predictive value), and number of referrals for additional screens per cancer correctly predicted were assessed for individuals above each points-based cutoff threshold.
To assess whether a more complex model increased model performance (AUROC), additional factors not widely available to clinicians or that may require additional examination were added to the initial model in turn (excluding individuals with missing data) and then with all factors significant at P < .1 added to a stepwise selection model.
A priori sensitivity/secondary analyses assessed the AUROC and stepwise model selection when the following:
including individuals with a history of non-upper gastrointestinal cancers; conducting multiple imputation for missing variables (using 10 imputations and combined using Rubin's rules); using different cancer follow-up periods; using different age periods; using different categories for smoking and BMI and separate variables for each esophageal condition; stratifying by age, sex, BMI, smoking history, and esophageal condition status at baseline to check model performance for importance patient subgroups; and excluding individuals who reported a history of Barrett's esophagus or esophagitis because these may already be undergoing endoscopic surveillance.
Further secondary analyses assessed the discriminative ability of the risk-prediction model identified in the primary analyses for total upper gastrointestinal cancer, because the tool could be used as triage to endoscopy, which could detect all types of gastric and esophageal cancers. For comparison we also used stepwise logistic regression to estimate factors widely available to clinicians associated with risk of total upper gastrointestinal cancer within 5 years (P < .1) and assessed the discriminative ability of a new pointsbased model. Analyses were conducted by using Stata/SE statistical software (version 14.1; College Station, TX).
Results
Participants
There were 502,640 participants in the UK Biobank, of whom 117,891 (23.5%) were excluded because they were aged younger than 50 years, 30,665 (6.1%) were excluded because of a history of cancer (or cancer within 6 months of baseline), and 4060 were excluded because of missing data (0.8%). This left 355,034 (70.7%) for inclusion in the final study cohort, among whom 220 individuals were diagnosed with EAC within 5 years. Individuals diagnosed with EAC were more likely to be older, male, smoke (current or former), have a higher BMI, have an existing esophageal or gastric condition, diabetes or hypertension, be below UK average height for their sex, and use nonsteroidal antiinflammatory drugs (NSAIDs), statins, or asthma inhalers (Table 1) . Mean follow-up time was 4.8 years (standard deviation, 0.6).
Non-participants
Individuals excluded because of incomplete data for some of the candidate predictor variables tended to be older, male, smoke (current), obese, tall, have an existing esophageal or gastric condition, diabetes or hypertension, or use NSAIDs, statins, or asthma inhalers.
Esophageal Adenocarcinoma Risk-Prediction Model: Coefficient-based Model
After applying the multi-phase stepwise procedure, the final coefficient-based model for predicting EAC development within 5 years included age at baseline, sex, BMI, smoking status, and history of diagnosis or treatment for esophageal conditions (Table 2) . This model had good discrimination, with AUROC of 0.80 (95% CI, 0.77-0.82; Figure 1A ). We found little evidence of overfitting in internal validation where the model showed equally good discriminatory ability (internally validated AUROC of 0.79). The performance of the model was statistically good by the goodness-of-fit test (HosmerLemeshow test, c 2 statistic ¼ 6.58, P ¼ .58) and the calibration curve ( Figure 1B ).
Esophageal Adenocarcinoma Risk-Prediction Model: Points-based Model
A points-based model assigned additional points on the basis of age (55-60 years, 1.5; 60-65 years, 2.5; Figure 2 ). The AUROC for the points-based model was similar (0.80; 95% CI, 0.77-0.82) to that of the coefficient-based model. The discriminative performances at each points-based cutoff threshold are provided in Table 3 . A cutoff threshold of 8þ points with the highest Youden's index (0.48) had a sensitivity of 77.5%, a specificity of 70.5%, and a positive predictive value of 0.16% ( Figure 1C) 
Sensitivity Analyses
No improvement in AUROC was apparent when additional variables not widely available to clinicians such as smoking status by pack-years and abdominal obesity were added to the model (Supplementary Table 2 ). The AUROC was similar in various sensitivity analyses, including when separating esophageal conditions by type and after multiple imputation (Supplementary Tables 3 and 4) .
Upper Gastrointestinal Cancers (Gastric and Esophageal Cancers)
The factors selected in the model for upper gastrointestinal cancer (gastric or esophageal cancers) within 5 years were the same as the model selected for EAC (age, sex, BMI, smoking status, history of esophageal conditions or treatments). The AUROC for predicting any upper gastrointestinal cancer of 0.74 (95% CI, 0.72-0.76) or for predicting risk of any gastric cancer within 5 years of 0.72 (95% CI, 0.69-0.76) were lower than that observed for EAC. The AUROC for predicting risk of esophageal cancer of any histologic type within 5 years was 0.76 (95% CI, 0.73-0.79) (Supplementary Table 3 ).
Because of similarity in structure, for simplicity, we report results by using the EAC points system. The 8-point cutoff again had the highest AUROC for any upper gastrointestinal cancer (0.68; 95% CI, 0.66-0.71), sensitivity was 66.3%, specificity was 70.5%, and positive predictive value was 0.31% cancer. This would represent 312 referrals for screening for every upper gastrointestinal cancer predicted (compared with 612 for EAC alone) (Supplementary Table 5 ).
Discussion
This cohort study using prospective data from the UK Biobank identified how combining established risk factors can aid risk prediction of EAC. The risk predictors identified included age at baseline, sex, tobacco smoking status, BMI, and a history of esophageal conditions or treatments including GERD ( Table 2) . The model was well-calibrated, and the discriminative performance was unchanged after internal validation using bootstrapping.
The factors included in the risk-prediction model are broadly consistent with factors identified in riskprediction models of Barrett's esophagus and EAC by using case-control methodology, 13, 14, 16, 18 which included BMI, smoking status, and esophageal conditions. However, the association between previous esophageal conditions and EAC risk was weaker than in previous studies, 13, 14 perhaps because of the lack of a specific question on gastroesophageal reflux symptoms or the minimization of recall bias in the current study. This indicates that the findings are robust to methodological differences. Other potential risk factors for EAC, ie, NSAIDs, were not confirmed to have utility in risk prediction, although this does not exclude a role for such factors in disease etiology. The discriminative ability of the model was similar after accounting for optimism using bootstrap samples and in analyses stratified by age, BMI, smoking history, and history of esophageal conditions or treatments, suggesting the finding may be robust to changing characteristics of the model or population. The discriminative ability was lower when stratified by sex, which highlights the importance of sex as a predictive factor.
Additional factors tested that may not be so widely available to clinicians and may require face-to-face assessment, ie, waist: hip ratio, did not improve the model performance in terms of AUROC. Therefore, it may not be necessary to make the additional effort it may take clinicians to collect information on these factors. Thus, the risk-prediction model could be used to develop an automated algorithm linked to clinical records to flag high-risk individuals to clinicians for screening or lifestyle advice, which could lower the cost and time of administering the test.
Despite low cost of administration, the absolute 5-year risk of EAC in individuals above the 8-point cutoff threshold (162.3 per 100,000) is still fairly low, which may limit cost-effectiveness of referring these individuals for further screening. This is especially true if the test is used to triage directly to endoscopy, even when considering the higher absolute 5-year risk of any upper gastrointestinal cancer that can be detected by endoscopy in individuals above this threshold (313.20 per 100,000). Nevertheless, it could be argued that these estimates are higher than the estimated absolute 5-year incidence in GERD patients of w100 per 100,000 in a recent review, 30 in whom guidelines recommend referral for endoscopy. 7 This study focused on a risk-prediction tool for triage to an intermediate step such as blood test, breath tests, Cytosponge, 31 or capsule endoscopies. 32 These additional triage steps could improve specificity and better identify high-risk individuals in whom endoscopic screening may be cost-effective. Future studies should c Not all cancers predicted will be detected during follow-up screens.
assess whether blood-based biomarkers could further enhance the specificity of this clinical risk prediction model, as has been demonstrated for Barrett's esophagus risk prediction. 15, 17 Full health economic modeling would be required to assess the cost-effectiveness of changes to screening practices.
Strengths and Limitations
A main strength is the cohort design using prospective data for this relatively rare cancer, which minimized recall bias and allowed the predictive value of age and sex to be estimated (which are typically matched on within case-control studies).
The self-report medical history without a specific question on gastroesophageal reflux symptoms lowers the accuracy of reporting of GERD history. The medication use was self-reported, which could limit the accuracy. 33 However, the follow-up interview with a trained health professional should reduce misreporting of medical history or medication use. We also did not have information on degree or duration of medication use for reflux symptoms, which added predictive value to a similar model in a previous study. 14 The generalizability of the UK Biobank to the general population has been criticized because of the healthy participant effect. 22 Further studies could validate the findings of the current study by using electronic clinical record databases, where symptom history may be better captured, because this would better reflect the level of information available to clinicians and be more generalizable.
The medical history data provided information on Barrett's esophagus or esophagitis rather than on either condition alone. Individuals with Barrett's esophagus or esophagitis remained in the primary analyses because esophagitis offers a potentially useful source of EAC risk prediction. A sensitivity analysis in which individuals with Barrett's esophagus or esophagitis were excluded did not alter the results, suggesting any potential detection bias because of endoscopic surveillance in some Barrett's esophagus patients was minimal.
Conclusion
In summary, a list of established risk factors including age, sex, BMI, smoking status, and esophageal conditions could aid risk prediction of EAC. These factors are consistent with previous risk-prediction studies, although the points attributed and positive predictive values for specific cutoffs require external validation.
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